Gilead Sciences (GILD) Cash from Operations Growth (5y) (2014 - 2026)

Gilead Sciences (GILD) Cash from Operations Growth (5y) (2014 - 2026) Analysis & Trends

Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Gsk 93,699,046.73 Bn 93,699,041.77 Bn 7.76 Bn
2 Eli Lilly 1,012.06 Bn 1,006.77 Bn 16.22 Bn
3 Johnson & Johnson 560.67 Bn 538.62 Bn 15.96 Bn
4 AbbVie 402.20 Bn 392.85 Bn 10.78 Bn
5 Merck 298.59 Bn 292.94 Bn 12.09 Bn
6 Amgen 188.77 Bn 176.74 Bn 5.87 Bn
7 Gilead Sciences 160.22 Bn 152.49 Bn 5.52 Bn
8 Pfizer 148.19 Bn 135.42 Bn -1.21 Bn
9 Bristol Myers Squibb 116.72 Bn 106.26 Bn 8.07 Bn
10 Novartis Ag 109.78 Bn 109.09 Bn -

Historic Data

Download Data
DateValue
Mar 31, 2026 -0.51%
Dec 31, 2025 11.67%
Sep 30, 2025 12.79%
Jun 30, 2025 -20.26%
Mar 31, 2025 4.12%
Dec 31, 2024 2.89%
Sep 30, 2024 10.25%
Jun 30, 2024 -10.77%
Mar 31, 2024 7.07%
Dec 31, 2023 -1.55%
Sep 30, 2023 -4.52%
Jun 30, 2023 8.25%
Mar 31, 2023 -5.14%
Dec 31, 2022 -1.39%
Sep 30, 2022 1.22%
Jun 30, 2022 -12.56%
Mar 31, 2022 -8.85%
Dec 31, 2021 -1.96%
Sep 30, 2021 -5.83%
Jun 30, 2021 -14.21%